The Clinic by Spotlight Health and Cancer Screening

Health screening and Rapid Diagnostics have become a powerful tool in detecting illness early. Cancer screening services and rapid diagnostic services are offered nationally but none are run in the same way as the The Clinic by Spotlight Health. Led by consultant oncologists and supported by expert, London based, cancer treating physicians and a general practitioner, this offers a unique opportunity to be assessed by The Clinic multidisciplinary team from presentation. In partnership with leading private health care providers, we aim to deliver a highly sophisticated screening and diagnostic pathway.

 

We offer both cancer screening packages (for those who do not have symptoms but are worried about cancer), as well as rapid diagnostics (for those who have symptoms and want to reach a diagnosis quickly).

To get in touch with us please leave your details here

RAPID DIAGNOSTICS SERVICES AND CANCER SCREENING BY A TEAM OF SPECIALISTS

  • 1 in 2 people will have a cancer diagnosis in their lifetime
  • Early diagnosis of cancer has clearly been shown to substantially improve survival outcomes.
  • As oncologists, our vision is clear, find cancer early, prior to the development of symptoms, and manage it as radically as possible.
  • The ICCN will provide specialist diagnostic clinics for rapid screening of the disease based in central London.
  • Clients will be able to benefit from a rapid cancer screening service uniquely led by a team of oncologists with a group of experts trained in the diagnosis and treatment of cancer.
  • The aim of this service is to rapidly diagnose or exclude cancer, offering greater peace of mind and providing a rapid pathway to expert cancer care.

Cancer Screening by cancer specialists

  • The COVID-19 pandemic led to more late diagnoses of cancer, meaning in some circumstances the opportunity to cure a patient was lost.
  • Due to a multitude of reasons, including the ongoing burden on healthcare services across the world, patients sadly began to present to doctors too late.
  • National cancer screening is limited to bowel, breast, and cervical in the UK. Our screening programs will aim to rule out several other types of cancer.
  • We have a robust ongoing referral pathway in place meaning if an abnormality is detected at your visit, specialist input is available to guide you.
  • Your data is kept confidential. Your file is only shared internally with healthcare staff who require them to complete your assessment. Your file is never shared with anyone else without your permission.

experience - what do we offer?

  • Expert clinical assessment by one of our highly recommended clinicians
  • Investigations (blood tests and scans are done on the same day)
  • Height/weight and vital signs check
  • Blood tests including tumour markers
  • ECG
  • Chest x-ray and abdominal/pelvic ultrasound
  • Imaging such as low-dose CT or whole-body MRI
  • Colonoscopy / upper endoscopy
  • Biopsies
  • A unique opportunity to undergo a personalised health appraisal following your assessment with one of our world-class oncology specialists
  • Why should I get tested?
    If you haven’t undergone an assessment in the last 12 months, we would recommend an ICCN-based oncology clinical evaluation.
  • When should I get tested?
    Early diagnosis of cancer has clearly been shown to substantially improve survival outcomes.
  • Why choose ICCN?
    A unique opportunity to undergo an assessment led and supervised by oncology specialists.

TRUCHECK™ PATHWAY

The Trucheck™ test is offered to asymptomatic clients only, it is offered alongside other established health screening tests which will be discussed with you. Trucheck™ is a blood-based test that is highly sensitive in detecting circulating tumour cells (CTCs) and CTC clusters released from malignant cells (cancer cells) into the bloodstream. It is able to detect up to 70 types of solid cancer tumours (accounting for approximately 81% of cancer cases in Europe) and has been validated across cohorts of over 40,000 patients. This sensitive and specific test is key for rapid early diagnosis. Successful treatment and improved survival rates are associated with detection at earlier stages. Trucheck™ has an overall sensitivity of between 82.5% to 88.2% for different types of cancers. It has a specificity of approximately 99%, correctly identifying 99 out of 100 cases that do not have cancer. Trucheck™ has been designed to complement standard health or cancer screening offering peace of mind to those with a negative test, but also guiding further investigations for those with positive test results. The Trucheck™ test has received US FDA Breakthrough Device Designation as well as European CE certification. It should be noted that Trucheck™ should always be used in conjunction with and the guidance of specially trained medical teams that can use the test as a compliment to established cancer screening. Blood tests are carried out in person at our sites in London where a face-to-face consultation, history taking and examination is carried out. If required, consultations can also be booked virtually. Complete consent to the Trucheck™ test must be obtained to ensure that the patient fully understands the next steps if a positive result is obtained. Results are received within four weeks, patients can visit their GP or be seen through our MDT team and join our fast track diagnostic route. Our MDT team are trained cancer specialists made up of a GP, oncologists, surgeon, physician and radiologist. They are then able to recommend any further necessary tests. If a patient receives a positive result, but no visible cancer is found a repeat blood test  is given three months later at no cost. This is repeated six months later if necessary.

PSA RESULTS PATHWAY

PSA blood tests are a fast and effective way to help guide a rapid diagnosis or exclusion of prostate disease including prostate cancer. Tests alone cannot be relied on and need to be followed up with further investigations. Our team at The Clinic offer counselling and further investigation to help with the rapid diagnosis or exclusion of cancer.